NCT02514083 2026-04-14
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
Clinical Trials
54 trialsNCT01589302 2026-04-13
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02649387 2026-02-10
MERIT
Mayo Clinic
Phase 2 Completed
NCT03204188 2026-01-30
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04230304 2025-12-30
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Mayo Clinic
Phase 2 Terminated
NCT02251548 2025-10-24
iFCR
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05564052 2025-10-07
VEGA
Janssen Research & Development, LLC
Phase 2 Completed
NCT01849263 2025-09-10
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02581930 2025-09-08
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03207555 2025-09-02
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04273139 2025-07-30
Ibrutinib + Venetoclax in Untreated WM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04477486 2025-07-09
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
AbbVie
Phase 2 Completed
NCT04062448 2025-05-25
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
Janssen Pharmaceutical K.K.
Phase 2 Completed
NCT02744612 2025-03-26
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT02824029 2025-02-17
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02643667 2025-01-08
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02207062 2025-01-07
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Completed
NCT02910583 2024-12-20
Captivate
Pharmacyclics LLC.
Phase 2 Completed
NCT02692248 2024-10-10
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT02532257 2024-09-24
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01500733 2024-09-19
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT02420912 2024-03-20
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT02869633 2023-10-23
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT03679624 2023-10-23
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02874404 2023-10-05
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University of Nebraska
Phase 2 Completed
NCT03267186 2023-08-01
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Stanford University
Phase 2 Completed
NCT04016805 2023-07-24
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03145480 2023-06-01
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Northwell Health
Phase 2 Terminated
NCT03121534 2023-02-17
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03873493 2022-12-19
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
AbbVie
Phase 2 Completed
NCT02604511 2022-12-07
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04209621 2022-03-09
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02736617 2022-01-05
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT03045328 2021-09-29
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Stanford University
Phase 2 Completed
NCT02943473 2020-12-16
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT02575300 2020-09-11
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01109069 2020-05-27
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 2 Completed
NCT02902965 2020-03-16
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Pharmacyclics Switzerland GmbH
Phase 2 Completed
NCT01478581 2020-03-10
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Pharmacyclics LLC.
Phase 2 Completed
NCT01614821 2020-01-21
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01980628 2019-10-16
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT01520519 2019-09-18
Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01980654 2019-04-16
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02272686 2018-12-05
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02415608 2018-09-20
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Stanford University
Phase 2 Terminated